FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Zura Bio Limited Stock AnalysisComprehensive stock analysis for Zura Bio Limited (ZURA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisZURA
ZURA
Zura Bio Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ZURA
Home🔹Stocks🔹Zura Bio Limited

Zura Bio Limited

🇺🇸ZURA•NASDAQ

Zura Bio Limited

🇺🇸ZURA•NASDAQ
Market cap
$494.94M
Sentiment

Your view on ZURA

Mkt Cap
$494.94M
Sentiment
Your view
ZURA
Zura Bio Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ZURA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Zura Bio Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Kimberly Ann Davis
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Kimberly Ann Davis
Headquarters
US
Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.

It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Zura Bio Limited, and the rating behind it. ZURA last traded at $5.21; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Zura Bio Limited. Starting points for Zura Bio Limited: EPS -$0.68, beta -0.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Zura Bio Limited. Zura Bio Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Zura Bio Limited. Trailing twelve-month EPS for Zura Bio Limited stands at -$0.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Zura Bio Limited. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Zura Bio Limited valued side by side against its closest peers. Zura Bio Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Zura Bio Limited, and how their positions are changing. At a $494.9M market value, institutional positions materially move Zura Bio Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Zura Bio Limited executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Zura Bio Limited. Zura Bio Limited is a $494.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Zura Bio Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Zura Bio Limited. Coverage tracks Zura Bio Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • AARD — Aardvark Therapeutics, Inc. Common Stock
  • ARCT — Arcturus Therapeutics Holdings Inc.
  • ASMB — Assembly Biosciences, Inc.
  • ENTA — Enanta Pharmaceuticals, Inc.
  • FHTX — Foghorn Therapeutics Inc.
  • IMRX — Immuneering Corporation
  • NAUT — Nautilus Biotechnology, Inc.
  • PYXS — Pyxis Oncology, Inc.

More Biotechnology companies

  • NBRVF — Nabriva Therapeutics plc
  • NBTX — Nanobiotix S.A.
  • NC6.AX — Nanollose Limited
  • NCEL — NewcelX Ltd.
  • NCNA — NuCana plc
  • NDTP — NDT Pharmaceuticals Inc.
  • NERV — Minerva Neurosciences, Inc.
  • NEU.AX — Neuren Pharmaceuticals Limited
  • NEUP — Neuphoria Therapeutics Inc.
  • NGNE — Neurogene Inc.
  • NICXF — Nicox S.A.
  • NIKI — Niki BioSolutions, Inc.

ETFs holding Zura Bio Limited

  • SBIO — ALPS Medical Breakthroughs ETF (0.29%)
  • VTWG — Vanguard Russell 2000 Growth ETF (0.02%)
  • VTWO — Vanguard Russell 2000 ETF (0.01%)
  • XSU.TO — iShares U.S. Small Cap Index ETF (CAD-Hedged) (0.01%)
  • RSSL — Global X - Russell 2000 ETF (0.01%)
  • VXF — Vanguard Extended Market ETF (0.00%)

News

Latest Market News